Clinical Trials

18 Sep 2019
- Clinical Trials
- Human Trials
Poxel initiates phase 1b multiple ascending dose trial for NASH drug candidate

By PBR Staff Writer

POXEL, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the initiation of a Phase 1b double-blind, randomized, placebo-controlled study in healthy subjects to evaluate the safety, tolerability and pharmacokinetics (PK) as well as support dose selection for a pivotal study of PXL065.
17 Sep 2019
Clinical Trials
Human Trials
Alnylam initiates APOLLO-B phase 3 study of patisiran for treatment of transthyretin amyloidosis with cardiomyopathy

By PBR Staff Writer

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated APOLLO-B, a global Phase 3 placebo-controlled clinical trial of patisiran, an intravenously administered RNAi therapeutic, for the treatment of transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy.
16 Sep 2019
Clinical Trials
Human Trials
Arrowhead presents initial top-line clinical data and preclinical data on RNAi candidates ARO-APOC3 and ARO-ANG3

By PBR Staff Writer

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented initial top-line clinical data at The Global Summit on Cardiology and Heart Diseases, being held in Dubai, UAE
16 Sep 2019
Clinical Trials
Human Trials
Novartis’ RMS drug ofatumumab achieves primary endpoints in phase III studies

By PBR Staff Writer

Novartis’ ofatumumab (OMB157) has achieved the primary endpoints in two phase III trials of relapsing multiple sclerosis (MS).
13 Sep 2019
Clinical Trials
Human Trials
Celgene’s QUAZAR AML-001 trial of CC-486 meets primary and key secondary endpoints

By PBR Staff Writer

Celgene Corporation has announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.
12 Sep 2019
Clinical Trials
Human Trials
VBI Vaccines announces phase 2a trial of VBI-1901 plus AS01B adjuvant system in recurrent glioblastoma

By PBR Staff Writer

VBI Vaccines has announced a collaboration with GlaxoSmithKline (GSK) to clinically evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, with GSK’s proprietary AS01B adjuvant system.
12 Sep 2019
Clinical Trials
Human Trials
Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study

By PBR Staff Writer

Roche announced that its lung cancer drug Tecentriq (atezolizumab) has significantly improved overall survival (OS) rate in the phase III IMpower110 study.
11 Sep 2019
Clinical Trials
Human Trials
Merck initiates phase 3 programme for evobrutinib in relapsing multiple sclerosis

By PBR Staff Writer

Merck announced the initiation of two global pivotal Phase III trials (EVOLUTION RMS 1 and 2) studying the efficacy and safety of evobrutinib, an oral, highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor in adult patients with relapsing multiple sclerosis (RMS).
10 Sep 2019
Clinical Trials
Human Trials
Esketamine nasal spray reduces depressive symptoms in two phase 3 studies

By PBR Staff Writer

Janssen Pharmaceutical said that the esketamine nasal spray along with the comprehensive standard of care (SOC) has met the primary efficacy endpoints of two phase 3 trials featuring adult patients with a major depressive disorder.
10 Sep 2019
Clinical Trials
Human Trials
AstraZeneca’s Imfinzi significantly improves OS in phase III SCLC trial

By PBR Staff Writer

AstraZeneca announced that its Imfinzi (durvalumab) has significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC) in the phase III Caspian study.

Drug Discovery

Research & Development

Sciwind secures China’s NMPA approval for Ecnoglutide injection

J&J announces Tecvayli-Darzalex combo approval from FDA for multiple myeloma

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer at CPHI Frankfurt 2025

Gerresheimer

Suppliers

No data found

Clinical Trials

Poxel initiates phase 1b multiple ascending dose trial for NASH drug candidate

Alnylam initiates APOLLO-B phase 3 study of patisiran for treatment of transthyretin amyloidosis with cardiomyopathy

Arrowhead presents initial top-line clinical data and preclinical data on RNAi candidates ARO-APOC3 and ARO-ANG3

Novartis’ RMS drug ofatumumab achieves primary endpoints in phase III studies

Celgene’s QUAZAR AML-001 trial of CC-486 meets primary and key secondary endpoints

VBI Vaccines announces phase 2a trial of VBI-1901 plus AS01B adjuvant system in recurrent glioblastoma

Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study

Merck initiates phase 3 programme for evobrutinib in relapsing multiple sclerosis

Esketamine nasal spray reduces depressive symptoms in two phase 3 studies

AstraZeneca’s Imfinzi significantly improves OS in phase III SCLC trial

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found